期刊文献+

国产那格列奈和孚来迪疗效临床观察 被引量:1

下载PDF
导出
出处 《实用糖尿病杂志》 2005年第1期38-39,共2页 Journal of Practical Diabetology
  • 相关文献

参考文献3

  • 1yoti B, Yulia H, Jerry R, James F. Mealtime Glucose Regulation with nateglinide in healthy volunteers, diabetes Care 2001;24 (1):74- 77.
  • 2谭少珍,周智广,唐炜立,朱旭萍,彭健,王建平,黄干.那格列奈治疗2型糖尿病的临床试验[J].中国医师杂志,2003,5(6):845-847. 被引量:11
  • 3Landgraf R, Bilo HJG. Repaglinide vs glibenclamide: a14 - week efficacy and safety comparison. Diabetes 1997 ;46(Suppl 1 ): 162A.

二级参考文献10

  • 1Sato Y,Nishikawa M,Shinkai H,et al.Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4- isopropylcyclohexyl)-carbonyl]- D-Phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals[].Diabetes Research and Clinical Practice.1991
  • 2Horton ES,Clinkingbeard C,Gatlin M,et al.Nateglinide alone or in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes[].Diabetes Care.2000
  • 3Shinkai H,Toi K,Kumashiro I,et al.N- acylphenylalanines and related compounds: a new class of oral hypoglycemic agents[].Journal of Medicinal Chemistry.1988
  • 4Hollander PA,Schwartz SL,Gatlin MR,et al.Importance of early insulin secretion : Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes[].Diabetes Care.2001
  • 5Hanefeld M,Bouter KP,Dickinson S,et al.Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia[].Diabetes Care.2000
  • 6Ikenoue T.Hypoglycemic and insulinotropic effects of a novel oral antidiabetic agent, (- ) -N- [(trans- 4 - isopropylcyclohexyl) - carbonyl] - DPhenylalanine(A-4166)[].British Journal of Pharmacology.1997
  • 7Fujitani S,Yada T.A novel D-phenylalanine-derivative hypoglycemic agent A-4166 increase cytosolic free Ca2+ in rat pancreatic beta- cells by stimulating Ca2+ influx[].The Journal of Endocrinology.1994
  • 8Keilson L,Mather S,Walter YH,et al.Synergistic effects of nateglinide and meal administration on insulin scretion in patients with type 2 diabetes mellitus[].The Journal of Clinical Endocrinology.2000
  • 9Lider TR.FDA approves nateglinide for treatment of type 2 diabetes[].American Journal of Health System Pharmacy.2001
  • 10Fujitani S,Okazaki K,Yada T.The ability of a new hypoglycemic agent , A-4166, compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic beta-cells under metabolic inhibition[].British Journal of Pharmacology.1997

共引文献10

同被引文献1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部